Loading...
Loading...
Application UK00918125478 · Registered
| Application Number | UK00918125478 |
| Status | Registered |
| Owner | SAGA Diagnostics AB |
| Filed | 2019-09-16 |
| Registered | 2020-01-09 |
| Renewal Due | 2029-09-16 |
| Type | Individual |
| Feature | Word |
| Attorney | See claim section below |
Yes. SAGAsign is currently a registered UK trademark, with renewal due on 2029-09-16. It is protected under UK intellectual property law and can be enforced against infringing uses.
The specification below is taken directly from the filed record at the UK IPO for each Nice class this trademark is registered in.
Biological preparations for medical purposes; Biological preparations for veterinary purposes; Chemical preparations for medical purposes; Chemical preparations for veterinary purposes; Nucleic acid sequences for medical and veterinary purposes; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Diagnostic preparations and materials; Chemical preparations for testing blood for medical purposes; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for use in dna analysis [medical]; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical use; Chemical reagents for veterinary use; Chemical test reagents [medical]; Chemical test reagents [veterinary]; Clinical diagnostic reagents; Clinical medical reagents; Diagnostic agents for medical use; Diagnostic biomarker reagents for medical purposes; Diagnostic chemical reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Diagnostic reagents for medical use; Diagnostic testing materials for medical use; Genetic identity tests comprised of reagents for medical purposes; In vitro diagnostic preparations for medical use; Indicators for medical diagnosis; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic test strips; Preparations for detecting genetic predispositions for medical purposes; Preparations for detecting mutation in prion genes for medical purposes; Reactants for medical diagnosis; Reagents and media for medical and veterinary diagnostic purposes; Reagents for analytical purposes [for medical purposes]; Reagents for analytical purposes [for veterinary purposes]; Reagents for blood grouping [for medical purposes]; Reagents for in-vitro laboratory use [for medical purposes]; Reagents for in-vitro laboratory use [for veterinary purposes]; Reagents for microbiological analysis [for medical purposes]; Reagents for microbiological analysis [for veterinary purposes]; Reagents for use in analysis [for medical purposes]; Reagents for use in analysis [for veterinary purposes]; Reagents for use in diagnostic tests [for medical purposes]; Reagents for use in diagnostic tests [for veterinary purposes]; Reagents for use with analyzers [for medical purposes]; Reagents for use with analyzers [for veterinary purposes]; Reagents for use in diagnostic pregnancy tests; Veterinary diagnostic reagents.
Analysis of human serum for medical research; Analysis of human tissues for medical research; Biological research, clinical research and medical research; Clinical research; Clinical trials; Conducting early evaluations in the field of new pharmaceuticals; Consultancy relating to laboratory testing; Consultancy relating to pharmaceutical research and development; Medical laboratory services; Medical research; Medical research laboratory services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing scientific information in the field of medical disorders and their treatment; Provision of information and data relating to medical and veterinary research and development; Research and development for the pharmaceutical industry; Research and development in the pharmaceutical and biotechnology fields; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Services for assessing the efficiency of pharmaceuticals; Services for assessing the efficiency of veterinary drugs.
Genetic counseling; Genetic testing of animals for diagnostic or treatment purposes; Laboratory analysis services relating to the treatment of persons; Medical and healthcare services; Monitoring of patients; Stem cell therapy services; Medical services; Analysis of human serum for medical treatment; Analysis of human tissues for medical treatment; Blood bank services; Bowel cancer screening services; Breast cancer screening services; Cervical cancer screening services; Colonoscopy screening services; Consultancy and information services relating to medical products; DNA screening for medical purposes; Genetic testing for medical purposes; Hepatitis screening services; Lung cancer screening services; Medical advice in the field of pregnancy; Medical analysis for the diagnosis and treatment of persons; Medical analysis services; Medical analysis services for cancer diagnosis and prognosis; Medical analysis services for the diagnosis of cancer; Medical analysis services relating to the treatment of patients; Medical analysis services relating to the treatment of persons; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the treatment of persons provided by a medical laboratory; Medical and health services relating to DNA, genetics and genetic testing; Medical care and analysis services relating to patient treatment; Medical consultations; Medical diagnostic services; Medical evaluation services; Medical laboratory services for the analysis of blood samples taken from patients; Medical laboratory services for the analysis of samples taken from patients; Medical screening; Medical services for the treatment of skin cancer; Medical services in the field of oncology; Medical testing for diagnostic or treatment purposes; Medical testing services relating to the diagnosis and treatment of disease; Prostate cancer screening services; Providing cancer screening services; Providing news and information in the field of medicine; RNA or DNA analysis for cancer diagnosis and prognosis; Services for the testing of blood; Services for the testing of sera; Services for the testing of urine; Services for the preparation of medical reports; Technical consultancy services relating to medical health; Testicular cancer screening services.
'SAGAsign' is a registered trademark on the UK IPO register, owned by SAGA Diagnostics AB. The application (UK00918125478) was filed on 16 September 2019 and registered on 9 January 2020. The registration is set to expire on 16 September 2029.
This mark is recorded under multiple classes: Class 5 (pharmaceuticals & medical preparations); Class 42 (scientific, IT & design services); Class 44 (medical, veterinary & beauty services).
The trademark is represented by Potter Clarkson LLP.
UK trademark UK00918125478 for the mark 'SAGAsign' in Class 5, 42, 44 is recorded on the UK IPO register as owned by SAGA Diagnostics AB. This covers one specific UK trademark record only — the same brand name may be owned by different parties in other classes, other countries, or as separate registrations.
Yes — the UK IPO records UK trademark UK00918125478 for the mark 'SAGAsign' as registered.
UK trademark UK00918125478 for the mark 'SAGAsign' is recorded in Class 5 (pharmaceuticals & medical preparations); Class 42 (scientific, IT & design services); Class 44 (medical, veterinary & beauty services). The filed specification reads: Class 5: Biological preparations for medical purposes; Biological preparations for veterinary purposes; Chemical preparations for medical purposes; Chemical preparations for veterinary purposes; Nucleic acid sequences for medical and veterinary purposes; Reagents for use in medical genetic testing; Reagents for use…
UK trademark UK00918125478 for the mark 'SAGAsign' was filed at the UK IPO on 16 September 2019 and registered on 9 January 2020.
UK trademark UK00918125478 for the mark 'SAGAsign' is currently recorded as valid until 16 September 2029, at which point it will need to be renewed with the UK IPO to remain in force.
Potter Clarkson LLP is listed as the attorney / representative of record for UK trademark UK00918125478 for the mark 'SAGAsign' on the UK IPO register.
This trademark has an attorney of record listed on the UK register. The firm has not yet claimed its listing on Trademark Dashboard.
Trademarks matching "SAGAsign" have been found on the following foreign registers. Exact matches appear first; where the name also appears inside longer filings, those are listed below as similar marks. A “Same applicant” badge appears next to a mark when the applicant name aligns with the source filing.
| Mark | Ref | Status | Filed |
|---|---|---|---|
| SAGASIGNSame applicant | 79297241 | 700 | 2020-03-05 |
UK trademark data is supplied by the Intellectual Property Office under the Open Government Licence v3.0.
US trademark data is supplied by the United States Patent and Trademark Office. Works of the US federal government are in the public domain under 17 U.S.C. §105.
The “About This Trademark” summary and FAQ above are AI-generated from the register data shown on this page. They are factual summaries only — always verify details against the official register before making legal decisions.